The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AG-G-56947     7-[(1R,2S,3R)-3-hydroxy-2- [(3S)-3...

Synonyms: SureCN10703857, CTK2F3401, 67786-53-2
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C05962


High impact information on C05962

  • Either PGI2 or its inactive hydrolysis product, 6-keto-PGF1 alpha, can be enzymically transformed via the 9-hydroxyprostaglandin dehydrogenase pathway to 6-keto-PGE1 [5].
  • Using platelet antiaggregatory activity as an index of stability, we found that PGI2 was largely inactivated within 10 minutes under the conditions used for incubating the slices (pH 7.4, 37 degrees C), while 6-keto-PGE1 was stable [6].
  • PGE2, PGE1, PGD2 and 6-keto-PGE1 each evoked a concentration-dependent inhibition of the leukotriene formation with IC50 values of 0.07 microM, 0.18 microM, 0.27 microM and 6 microM respectively [7].
  • HPLC fractions containing i-6-keto-PGE1, and coeluting with 6-keto-PGE1 standard, exhibited potent inhibition of platelet aggregation [8].
  • These studies were performed to examine the effects of 6-keto-prostaglandin E1 (6-keto-PGE1) on coronary artery blood flow and reflex cardiovascular regulation [1].

Biological context of C05962


Anatomical context of C05962


Associations of C05962 with other chemical compounds


Gene context of C05962


Analytical, diagnostic and therapeutic context of C05962


  1. 6-Keto-prostaglandin E1 is a potent coronary vasodilator and stimulates a vagal reflex in dogs. Panzenbeck, M.J., Hintze, T.H., Kaley, G. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  2. 6-Keto-prostaglandin E1-stimulated bone resorption in organ culture. Dewhirst, F.E. Calcif. Tissue Int. (1984) [Pubmed]
  3. Placental vascular responses to 6-keto-prostaglandin E1 in the near-term sheep. Schwartz, D.B., Phernetton, T.M., Stock, M.K., Rankin, J.H. Am. J. Obstet. Gynecol. (1983) [Pubmed]
  4. Effects of 6-keto-prostaglandin E1 on ascitic hepatoma-130 in vivo comparison with chemotherapeutic agents. Kobayashi, H., Ojima, M., Satoh, H. Prostaglandins (1985) [Pubmed]
  5. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification. Wong, P.Y., Lee, W.H., Chao, P.H., Reiss, R.F., McGiff, J.C. J. Biol. Chem. (1980) [Pubmed]
  6. Prostaglandin-related renin release from rabbit renal cortical slices. Spokas, E.G., Wong, P.Y., McGiff, J.C. Hypertension (1982) [Pubmed]
  7. Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate. Physiological triggers and modulation by prostanoids. Haurand, M., Flohé, L. Biochem. Pharmacol. (1989) [Pubmed]
  8. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit. Pieroni, J.P., Dray, F., Pace-Asciak, C.R., McGiff, J.C. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  9. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed. Hyman, A.L., Kadowitz, P.J. J. Pharmacol. Exp. Ther. (1980) [Pubmed]
  10. Effects of 6-keto-prostaglandin E1 on perinatal pulmonary vascular resistance. Tod, M.L., Cassin, S. Proc. Soc. Exp. Biol. Med. (1981) [Pubmed]
  11. Hypotensive response to prostacyclin and 6-keto-PGE1 following hepatectomy in the rat. Van Dam, J., Stinger, R.B., Penhos, J.C., Ramwell, P.W., Kot, P.A. Proc. Soc. Exp. Biol. Med. (1984) [Pubmed]
  12. Enzymatic inactivation of 6-keto-prostaglandin E1 in vitro: comparison with prostaglandin E1. Berry, C.N., Hoult, J.R., Griffiths, R.J., Moore, P.K. Biochem. Pharmacol. (1984) [Pubmed]
  13. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue. Jackson, E.K., Herzer, W.A., Zimmerman, J.B., Branch, R.A., Oates, J.A., Gerkens, J.F. J. Pharmacol. Exp. Ther. (1981) [Pubmed]
  14. 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells. Oliva, D., Bernini, F., Corsini, A., Nicosia, S. Biochem. Pharmacol. (1984) [Pubmed]
  15. Formation of 6-keto prostaglandin E1 in mammalian kidneys. Griffiths, R.J., Moore, P.K. Br. J. Pharmacol. (1983) [Pubmed]
  16. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Gryglewski, R.J., Szczeklik, A., Wandzilak, M. Biochem. Pharmacol. (1987) [Pubmed]
  17. Effects of protein kinase C activation on human platelet cyclic AMP metabolism. Bushfield, M., Hopple, S.L., Gibson, I.F., Murdoch, F.A., MacIntyre, D.E. FEBS Lett. (1987) [Pubmed]
  18. Inhibition of vasoconstrictor responses by 6-keto-PGE1 in the feline mesenteric vascular bed. Lippton, H.L., Chapnick, B.M., Hyman, A.L., Kadowitz, P.J. Prostaglandins (1980) [Pubmed]
  19. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin. Miyamori, I., Morise, T., Yasuhara, S., Takeda, Y., Koshida, H., Takeda, R. British journal of clinical pharmacology. (1985) [Pubmed]
  20. Atrial natriuretic peptide-induced increase of glomerular filtration rate, but not of natriuresis, is mediated by prostaglandins in the rat. Pomeranz, A., Podjarny, E., Rathaus, M., Shilo, L., Shenkman, L., Bernheim, J. Mineral and electrolyte metabolism. (1990) [Pubmed]
  21. Inhibition of platelet aggregation by 6-keto-PGE1; lack of an effect on cyclic GMP levels. Pontecorvo, E.G., Myers, C.B., Lippton, H.L., Kadowitz, P.J. Prostaglandins and medicine. (1981) [Pubmed]
  22. The effect of 6-keto-prostaglandin E1 on human lymphocyte cAMP levels. Mastacchi, R., Fadda, S., Tomasi, V., Barnabei, O. Prostaglandins and medicine. (1980) [Pubmed]
  23. Dacron inhibition of arterial regenerative activities. Greisler, H.P., Schwarcz, T.H., Ellinger, J., Kim, D.U. J. Vasc. Surg. (1986) [Pubmed]
  24. Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclin. Quilley, C.P., Wong, P.Y., McGiff, J.C. Eur. J. Pharmacol. (1979) [Pubmed]
  25. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation. Berry, C.N., Hoult, J.R. Pharmacology (1983) [Pubmed]
  26. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney. Schwertschlag, U., Stahl, T., Hackenthal, E. Prostaglandins (1982) [Pubmed]
WikiGenes - Universities